Giovanni Ragozzino
Caserta, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Letter by Ragozzino and Mattera et al Regarding Article, "What Exactly Is Cardiometabolic HFpEF: A Phenotype or an Endotype?"
Journal: Circulation. Heart failure
Published: June 24, 2026
Epicardial adipose tissue between biological complexity and clinical readiness.
Journal: European journal of internal medicine
Published: May 28, 2026
Comment on Lin et al. Reconsidering Adipose Tissue Lipolysis Dysfunction: Evidence for a Distal Machinery Defect Beyond Insulin Resistance.
Journal: Diabetes
Published: May 20, 2026
Interpreting Glucagon-Like Peptide-1 Receptor Agonist-Associated Cough in Observational Data.
Journal: JAMA otolaryngology-- head & neck surgery
Published: May 14, 2026
Beyond the emperor's clothes: Reframing when steatosis constitutes disease.
Journal: Journal of hepatology
Published: May 11, 2026
Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study.
Journal: Frontiers in endocrinology
Published: April 14, 2026
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
Journal: Journal of translational medicine
Published: April 01, 2026
Early integrated management and characteristics of adult patients with overweight and obesity: a modified delphi consensus study in Italy.
Journal: Journal of endocrinological investigation
Published: March 30, 2026
Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.
Journal: EXCLI journal
Published: October 30, 2025
Last Updated: 09/26/2026